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A b s t r a c t  
D-Limonene is a dietary monoterpene with significant anticancer activity against many cancer types 
in preclinical and clinical studies. The study is designed to investigate synergistic anticancer effects 
of limonene and BEZ235 combination in COLO-320 and HCT-116 colon cancer cells. Cells were 
treated with both the drugs alone and in combination and the effects on cell viability; cell migration 
and clonogenic potential were examined. Results show that both drugs exhibited dose and time 
dependant cytotoxicity on the cell lines tested. Composing analysis of the drug combination effects 
revealed the strong synergistic interaction of the combination. Our results also indicate that COLO-
320 cells were more sensitive for anticancer effects of the drugs than HCT-116 cells. The presence 
of Ras and PI3K mutations in HCT-116 cells could possibly be one of the main reasons for the 
observed outcome as compared to the wild type expressions of them in COLO-320 cells.  
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Introduction 
Colorectal cancer (CRC) is the third leading cause of cancer death 
in both men and women and the second leading cause of cancer 
death when men and women are combined [1]. It shows significant 
geographical, racial and ethnic variation in its incidence rate and 
pattern. Most of CRCs are sporadic, whereas 10% have a clear 
genetic background. These include familial adenomatous polyposis 
(FAP) and hereditary non-polyposis colorectal cancer (HNPCC) are 
dominantly inherited conditions with 100% and 80% life-time risk of 
developing colorectal cancer, respectively. The mutations in 
adenomatous polyposis coli (APC) and mismatch repair (MMR) 
genes are responsible for these two conditions [2]. These same 
genes also play a key role in the formation of sporadic colorectal 
cancers. 
Most of CRCs are thought to develop slowly through an orderly 
series of events known as adenoma carcinoma sequence. Here, 
normal colonic mucosa is transformed into adenoma, which then 
transforms into adenocarcinoma [3]. Therefore early detection and 
removal of adenomatous polyps can prevent colorectal cancer. 
Majority of the colorectal cancers (approximately 96%) are 
adenocarcinoma type which is cancer that develops in glandular 
cells on the inner lining of the colon and rectum  [4] .  
Advances in molecular pathogenesis of CRC have aided in 
formulating both preventive and therapeutic strategies. Ras and 
PI3K are complex signaling pathways that are critical for cell 
proliferation and apoptosis. Aberrant activation of these signaling 
pathways has been observed in the development of CRC with 
enhanced risk of tumor growth, angiogenesis and metastasis [5].     
K-ras and PI3K mutations are one of the commonest genetic 
alterations seen in CRC with a frequency of about 30% and 17 % 
respectively [6]. Therefore, inhibition of these signaling pathways 
requires a multitargeted approach.  Natural compounds with 
anticancer activity are better chemo preventive and/or therapeutic 
alternatives because of their pleiotropic properties.  
D-limonene is a monocyclic monoterpene with a lemon-like odor 
and is a major constituent in several citrus oils (orange, lemon, 
mandarin, lime, and grapefruit). It is widely used as a flavor and 
fragrance additive in food industry. Limonene has been clinically 
used to dissolve cholesterol containing gallstones [7] and because 
of its potential for gastric acid neutralization, it has also been used 
to relieve heartburn and gastro esophageal reflux disorder (GERD) 
[8]. Limonene acts on many cellular targets in cancer cells such as; 
immune modulation, modulating chemical carcinogenesis, anti-
oxidant activity and apoptosis. In preclinical cancer models, it has 
been shown to prevent or delay the growth of a number of cancer 
types including lymphomas [9], mammary [10], gastric [11], liver 
[12], lung [13], and prostate cancer [14]. It is also shown to 
decrease the number of aberrant crypt foci (ACF) in azoxymethane      
induced putative preneoplastic carcinogenesis in rodents [15]. For 
many years azoxymethane induced ACF has been used as 
surrogate biomarkers in the screening of anticancer agents. 
NVP-BEZ 235 (Novartis) is a dual pan-class I PI3K and mTOR 
kinase inhibitor that has been demonstrated to reduce tumor 
growth in a number of different xenograft and several genetically 
engineered mouse models and is currently in clinical trials [16]. It 
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types, including breast cancer, multiple myeloma, and sarcoma [17, 
18]. The compound has also been tested in colorectal cancer with 
coexistent mutations of KRAS and PIK3CA [19].  
The objective of this study is to determine synergistic anticancer 
activity of limonene and BEZ in colon cancer cells and also to find if 
there is any difference in response between K-ras and PI3K 
mutation vs. wild type cells. 
 
Materials and methods  
 
Cell lines and drugs 
  
COLO-320 ( wild type KRAS and PI3KCA) and HCT-116 (mutant 
KRAS-G13D; and PI3KCA-H1047R) colon cancer cell lines were 
obtained from the American Type Culture Collection (ATCC, 
Manassas, VA), and was maintained in DMEM culture medium 
(Gibco BRL-Invitrogen) supplemented with 10% FBS (Hi-Media), 
100 U/ml penicillin and 100 μg/ml streptomycin (Hi-Media) at 37o C 
in  an incubator with 5% CO2.  D-Limonene was procured from 
Sigma and NVP-BEZ235 (Novartis) was procured from Cayman 
chemicals (Prolab Marketing Pvt Ltd, New Delhi, India). 
 
Cell viability assay 
 
The effect of limonene and/or BEZ235 on the cell viability of colon 
cancer cells was determined by MTT assay. Briefly, cells were 
seeded at a density of 1 X 104 cells per well in 96-well plates and 
treated either with limonene or BEZ235 and also with their 
combinations, at specified concentrations for 24 and 48h. For 
combination effects the cells were treated with both the drugs 
simultaneously as well as sequentially. In simultaneous treatment, 
the cells were treated with limonene and BEZ for 24 and 48h 
continuously. While in sequential treatment, cells were pre-treated 
with either limonene or BEZ for 12h, followed by the exposure to 
the other agent for a total of 24 and 48h.  
Cells were incubated with the MTT reagent (5 mg/ml in DMEM) for 
3h at 37o C, followed by solubilization of the formazan crystals with 
DMSO for 10min. Absorbance was measured at 570 nm using a 
microplate analyzer (BioTEK, synergy 4 multimode microplate 
reader). The percent cell viability was calculated using the following 
formula; % cell viability= OD of test/OD of control x 100. 
 
In vitro scratch assay 
 
The in vitro scratch assay is an easy, low-cost and well-developed 
method to measure cell migration in vitro. Compared to other 
methods, the in vitro scratch assay is particularly suitable for 
studies on the effects of cell-matrix and cell-cell interactions on cell 
migration, mimic cell migration in vivo, which in general, occurs 
during embryogenesis or tissue regeneration or cancer metastasis. 
Cells were seeded at a density of 5××104 in 6 well plates and the 
monolayer of 80% confluent cells were treated for 48h either with 
limonene or BEZ235 and also with their combinations (in the format 
of both drugs at once) at the doses indicated. The serum 
concentration in the growth media was decreased to minimize cell 
proliferation, but just sufficient to prevent apoptosis and/or cell 
detachment. After 48h of treatment, the drug containing medium 
was removed and a scratch was created with a sterile p200 pipette 
tip and washed twice with PBS to remove floating cells and plates 
were incubated after adding complete DMEM with 5% FBS. Cell 
migration was monitored by capturing images at 0, 24 and 48h 
using an inverted phase microscope (Olympus, CKX41). Gap area 
was measured relative to the total cell-covered area with Wimasis 
image analysis software. The effect of drug treatment was 
measured by a reduction in the % cell migration at each time 
interval compared to untreated control using the following formula; 
% Cell migration= (Scratch area at 0h-Scratch area at specific time 
point)/Scratch area at 0h x100. 
 
Colony formation assay 
Clonogenic cell survival is the method of choice to determine cell 
reproductive death after treatment with ionizing radiation, but can 
also be suitably adopted to determine the effects of cytotoxic 
agents. More over colony-forming assays are good indicators of 
drug- induced cytotoxicity and effects on tumor cell clonogenicity 
than the conventional cell viability methods [20]. The clonogenic 
cell survival assay determines the ability of a cell to proliferate 
indefinitely, thereby retaining its reproductive ability to form a large 
colony or a clone which is visible to the naked eye. Cells were 
seeded (5×104) in 6-well culture plates and treated with various 
doses of drugs either single or in combination, as indicated for 48h. 
Cells were trypsinised and approximately 100 cells for each drug 
concentration was seeded into fresh 6-well culture plates and 
incubated for another 2 -3 weeks with change of fresh media once 
in 3days. Colonies were fixed in methanol and stained with 0.5% 
crystal violet dye for 30min and colonies containing >50 cells were 
counted under inverted phase contrast microscope.  
Analysis of combination effects using CompuSyn 
software 
Further the anticancer effects of limonene and BEZ235 
combination in COLO-320 and HCT-116 cells were analyzed using 
CompuSyn software [21] for synergism, additive or antagonistic 
effects based on Combination Index (CI). If the CI of less than, 
equal to, and more than 1 indicate synergistic, additive and 
antagonistic effects, respectively. 
Statistical analysis 
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Statistical analysis was carried out using ‘GraphPad Prism 
Software’ (San Diego, USA). All experiments were performed in 
triplicate and repeated three times. Data were presented as mean 
± standard deviation (SD) and analyzed by one-way analysis of 
variance (ANOVA) followed by Dunnett’s multiple comparison test. 
The level of significance was set at p 0.05. 
Results  
Limonene and BEZ235 inhibits cell proliferation 
Cells were treated with increasing doses of limonene (100-3000µm) 
and BEZ235 (10-1000nm) for 24 & 48h and viability was 
determined by MTT assay. Drug treatment exhibited significant 
difference in viability compared to control (P<0.05). When tested 
individually both the drugs inhibited cell proliferation in dose and 
time dependent manner (Figure 1). Under the experimental 
conditions, the calculated IC50 values in COLO-320 were at 950µm 
and 104nm for limonene and BEZ respectively; whereas in HCT-
116 the IC 50 values for limonene and BEZ were at 1995µm and 
98nm respectively.  
Cells were treated with different combinations of the drugs added 
simultaneously as well as sequentially and cell viability was 
determined as described previously by MTT assay. The 
combination of varying doses of limonene and BEZ produced 
maximum antiproliferative activity at 48h when compared with the 
treatment of either agents alone in both the cell lines. The 
combination of LIM+BEZ at a concentration of 1000+100 produced 
highest antiproliferative activity in COLO-320; whereas in HCT-116 
the combination at a concentration of 1500+100 showed highest 
activity (Figure 2.A.D).  
While testing combination effects the cells were exposed to drugs 
in different formats as mentioned above. Antiproliferative effect was 
more when the cells were exposed to both drugs simultaneously 
than sequential treatment (83% vs. 60% or 68% for COLO-320: 




Figure 1: Effect of Limonene and BEZ on cell viability Showing the effect of limonene and BEZ on cell viability in COLO-320 (A.B); HCT-116 
(C.D) CRC cell lines.  Cells were treated for 24 & 48h and viability was determined by MTT. Data were expressed as mean ± SD (n=3). *p ˂ 0.05 








Figure 2: Effect of limonene and BEZ combination of on cell viability. Combination effect of limonene (LIM) and BEZ on anti-proliferative activity 
in COLO-320 & HCT-116 cells. A.D: Cells were treated with limonene in combination with BEZ at the same time. B.E: Cells were pre-treated with 
limonene for 12h followed by exposure to BEZ. C.F: Cells were pre-treated with BEZ for 12h followed by exposure to limonene.  Cells were 
treated for a total of 24 & 48h and viability was determined by MTT. Data were expressed as mean ± SD (n=3). *p ˂ 0.05 
Effects of limonene and BEZ235 on cell migration 
In vitro scratch assay was performed to study the effects of 
limonene and BEZ235 on cell migration in COLO-320 & HCT-116 
cell lines (Figure 3.A.B).  Lower doses of limonene (250, 500µm) 
and BEZ (25, 50nm) and their possible combinations were selected 
for the study only to minimize the cytotoxicity. In control group cell 
migration into the scratch was 100% in 48h resulting complete 
closure of the gap, whereas drug treatment alone or in combination 
caused a significant inhibition of cell migration in both the cell lines 
(P<0.05).  The maximum inhibition of % cell migration observed at 
48h was 54.75, 67.7 in COLO-320 and HCT-116 cells respectively 
at the highest concentration of LIM+BEZ (500+50).  
 
Figure 3: Limonene and BEZ inhibits cell migration. Effect of limonene and BEZ combinations on cell migration in COLO-320 (A); HCT-116 (B) 
cell lines.  Cells were treated for 48h and scratch images were captured at 0, 24 and 48h and analyzed as described in materials and methods. 
The percent cell migration was expressed as mean ± SD (n=3). *p ˂ 0.05
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Combination of limonene and BEZ235 inhibits colony 
formation 
Clonogenic assay was performed to study the effects of limonene 
(250, 500µm), BEZ (25, 50nm) and their combinations (Figure 4.A). 
Represent images of the assay were shown in Figure 4.B.  Both the 
drugs at high concentrations resulted a significant inhibition of 
colony formation (%) compared to control (P<0.05).  Drug 
combinations were more effective than either of the drugs alone. 
LIM+BEZ at high concentration (500+50) showed maximum 
inhibition of 53.66; 51.76 in COLO-320 & HCT-116 cells 
respectively. 
 
Figure 4: Limonene and BEZ inhibits colony formation. Effect of limonene and BEZ combinations on colony formation of COLO-320 and HCT-
116 cell lines. A: The percent inhibition of colony formation at different drug combinations expressed relative to untreated cell control considering 
as zero; B: Images of colonies that were stained with 0.5% crystal violet reagent. The data were expressed as mean ± SD (n=3). *p ˂ 0.05 
Synergistic anticancer activity of limonene and BEZ 
The interaction of drug combinations was analyzed by CompuSyn 
software and CI values were generated to determine synergy, 
additive or antagonistic effects. The combination of LIM+BEZ on 
cell viability was strongly synergistic (CI˂1) at 1000+50; 1000+100 
in COLO-320 when the drugs were exposed at the same time. In 
HCT-116 also the combination at 1500+50; 1500+100 produced 
strong synergism in the same format. While in pretreatment formats 
all the combinations were shown to be antagonistic (CI ˃1) in both 
the cell lines (Table 1.A).  
In COLO-320 the combination shows strong synergism on inhibition 
of cell migration at 250+50; 500+25 and 500+50; whereas it shows 
a weak synergistic interaction on colony formation at the dose of 
500+25. However in HCT-116 the combination at 500+25; 500+50 
produced strong synergism on inhibition of cell migration and 
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Table 1: Combination Index (CI) values of limonene and BEZ combination effect on COLO-320 and HCT-116 cell lines 
 
A: Effect of combination treatment on anti-proliferative activity. Cells were treated with the drug combination simultaneously as well as 
sequentially as described in material & methods. B: Effect on cell migration and colony formation. Synergistic interaction is determined if CI<1, an 




The presence or absence of a variety of cellular targets in various 
colon cancers guide not only to design therapeutic regimen but 
provides information on clinical outcome. A range of molecular 
markers are known and currently being investigated for prognostic 
and predictive utility in colorectal cancer. Ras and PI3K signaling 
pathways are one of such biomarkers and key regulators of cell 
proliferation and apoptosis. Mutations in these signaling pathways 
are frequently observed in the genesis of CRC. Generally point 
mutations in K-ras gene are believed to be among the earliest 
events in colorectal tumor genesis [21]. Therefore we designed the 
study to investigate how K-ras and PI3K mutations influence the 
anticancer effects of the drugs by testing on COLO-320 (wild) and 
HCT-116 (mutant) colon cancer cell lines. 
Although limonene has been tested as an anticancer agent against 
various cancers but its potential application in combination with 
other anticancer drugs has not been thoroughly explored. 
Therefore in this study we tested limonene and BEZ235 
combination for synergistic anticancer activity. Limonene is a 
natural dietary monoterpene with lemon like flavor. Evidence from a 
phase I clinical trial showed that limonene is well tolerated and may 
have clinical activity in cancer patients [22]. Our study 
demonstrated that limonene shows anticancer effects relatively at 
high concentrations, but lack of toxicity even at high doses as 
shown in various clinical studies makes it a potential anticancer 
agent when used in combination with other cytotoxic drugs. 
We found that combination treatments were more effective than 
either of the drugs alone. In CompuSyn analysis also the drug 
combination effects revealed the strong synergistic interaction. In 
particular, we noted that all the combinations with high 
concentrations of limonene were strongly synergistic in both the 
cells.  It is also evident from our results that exposure of both drugs 
at the same time was more effective than pre-treatment format. Our 
results also indicate that COLO-320 cells were more sensitive for 
anticancer effects of the drugs than HCT-116 cells. The presence 
of Ras and PI3K mutations in HCT-116 cells could possibly be one 
of the main reasons for the observed outcome as compared to the 




In conclusion the results demonstrate that combination treatment of 
limonene and BEZ235 elicits synergistic anticancer effects in 
COLO-320 and HCT-116 colon cancer cell lines. Although further 
studies are required to determine whether or not this drug 
combination yield similar anticancer effects in other cancer cell 
lines, we suggest that this study may be useful to identify potential 
anticancer compounds. Also studies are under progress to 
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